Table 1 FDA approved PARP inhibitors for clinical use and associated indications

Olaparib

Maintenance therapy for platinum sensitive, recurrent, BRCA mutated ovarian cancer after ≥ 3 prior chemo regimens

Maintenance therapy for platinum sensitive, recurrent, epithelial ovarian, fallopian, and peritoneal cancer with confirmed or suspected BRCA mutations

Treatment of metastatic, HER2 negative, BRCA mutated breast cancer who previously received chemotherapy

Treatment of metastatic, BRCA mutated, pancreatic cancer

Rucaparib

Treatment of platinum sensitive, recurrent ovarian, fallopian, and peritoneal cancer

Niraparib

Maintenance therapy for platinum sensitive, recurrent ovarian, fallopian, and peritoneal cancer

Talazoparib

Treatment of BRCA mutated, HER2 negative, advanced breast cancer